Covered recipient · General Payments record
WILLIAM SEGER
Allopathic & Osteopathic Physicians Family Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$1,710.22
126 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,697.87 | 125 |
| Education | $12.35 | 1 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | $367.91 | 11 |
| PFIZER INC. | $191.37 | 17 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $149.94 | 12 |
| Sunovion Pharmaceuticals Inc. | $124.62 | 18 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $110.17 | 9 |
| GlaxoSmithKline, LLC. | $110.00 | 15 |
| Merck Sharp & Dohme Corporation | $108.04 | 11 |
| Novartis Pharmaceuticals Corporation | $79.57 | 5 |
| Janssen Pharmaceuticals, Inc | $71.39 | 4 |
| SANOFI-AVENTIS U.S. LLC | $60.34 | 2 |
| Astellas Pharma US Inc | $58.22 | 4 |
| Kowa Pharmaceuticals America, Inc. | $45.06 | 3 |
| Abbott Laboratories | $39.32 | 2 |
| Novo Nordisk Inc | $36.05 | 3 |
| Genentech USA, Inc. | $31.98 | 2 |
| Amgen Inc. | $25.89 | 2 |
| SI-BONE, Inc. | $23.94 | 1 |
| Ethicon US, LLC | $22.27 | 1 |
| Amarin Pharma Inc. | $15.84 | 1 |
| Mylan Specialty L.P. | $15.70 | 1 |
| SANOFI PASTEUR INC. | $11.39 | 1 |
| E.R. Squibb & Sons, L.L.C. | $11.21 | 1 |
Page 3 of 3; records 101–126 of 126 matching records. This page contains 26 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
WILLIAM SEGER
NPI 1417927971 · CMS profile ID 199728
Allopathic & Osteopathic Physicians / Family Medicine
FORT WORTH, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–126 of 126 matching records. This page contains 26 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1417927971?year=2019&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- WILLIAM SEGER, NPI 1417927971, CMS profile ID 199728. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–126 of 126 matching records. This page contains 26 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1417927971?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). WILLIAM SEGER, NPI 1417927971, CMS profile ID 199728. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–126 of 126 matching records. This page contains 26 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1417927971?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- WILLIAM SEGER, NPI 1417927971, CMS profile ID 199728, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–126 of 126 matching records. This page contains 26 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1417927971?year=2019&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
126 matching records · $1,710.22 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–126 of 126.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | $3.69 | 02/17/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670209823 | CMS |
| Abbott Laboratories | $19.66 | 02/15/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 664391523 | CMS |
| Merck Sharp & Dohme Corporation | $8.09 | 02/15/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695295583 | CMS |
| Astellas Pharma US Inc | $14.71 | 02/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655755715 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $11.43 | 02/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 684931321 | CMS |
| PFIZER INC. | $11.51 | 02/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672179840 | CMS |
| Novartis Pharmaceuticals Corporation | $17.10 | 02/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 660200541 | CMS |
| PFIZER INC. | $4.99 | 02/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672232207 | CMS |
| Sunovion Pharmaceuticals Inc. | $1.08 | 02/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688096551 | CMS |
| AstraZeneca Pharmaceuticals LP | $121.59 | 02/07/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685583707 | CMS |
| Novo Nordisk Inc | $12.29 | 02/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 668791571 | CMS |
| E.R. Squibb & Sons, L.L.C. | $11.21 | 01/31/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651366029 | CMS |
| GlaxoSmithKline, LLC. | $8.41 | 01/31/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670205603 | CMS |
| GlaxoSmithKline, LLC. | $1.24 | 01/31/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671107191 | CMS |
| PFIZER INC. | $23.36 | 01/31/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672133109 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $7.13 | 01/30/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 700356105 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.22 | 01/30/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 684931319 | CMS |
| Genentech USA, Inc. | $13.98 | 01/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681352391 | CMS |
| Merck Sharp & Dohme Corporation | $11.99 | 01/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695247723 | CMS |
| Sunovion Pharmaceuticals Inc. | $15.49 | 01/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688096549 | CMS |
| Sunovion Pharmaceuticals Inc. | $3.12 | 01/17/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688096547 | CMS |
| Amgen Inc. | $10.88 | 01/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 663185859 | CMS |
| AstraZeneca Pharmaceuticals LP | $136.63 | 01/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685654763 | CMS |
| GlaxoSmithKline, LLC. | $8.62 | 01/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671026817 | CMS |
| AstraZeneca Pharmaceuticals LP | $12.04 | 01/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685081404 | CMS |
| PFIZER INC. | $10.67 | 01/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672162843 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,891,022.48 | 334 |
| PY2024 | Recipient | $3,200.00 | 1 |
| PY2024 | Principal investigator | $3,725,318.03 | 333 |
| PY2023 | Principal investigator | $5,662,721.18 | 2,144 |
| PY2022 | Principal investigator | $6,424,241.89 | 584 |
| PY2021 | Principal investigator | $6,369,174.56 | 321 |
| PY2020 | Principal investigator | $1,991,482.37 | 385 |
| PY2019 | Principal investigator | $1,391,006.52 | 909 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
334 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ModernaTX, Inc. | $54.64 | 12/23/2025 | Non-covered Recipient Entity BENCHMARK RESEARCH | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996808 |
| Principal investigator 1 | Seqirus USA Inc | $3,268.53 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266119 |
| Principal investigator 1 | Seqirus USA Inc | $3,268.53 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266121 |
| Principal investigator 1 | Seqirus USA Inc | $3,268.53 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266123 |
| Principal investigator 1 | Seqirus USA Inc | $3,268.53 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266125 |
| Principal investigator 1 | Seqirus USA Inc | $3,268.53 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266127 |
| Principal investigator 1 | Seqirus USA Inc | $3,268.53 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266185 |
| Principal investigator 1 | Seqirus USA Inc | $3,268.53 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266187 |
| Principal investigator 1 | Seqirus USA Inc | $3,268.53 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266189 |
| Principal investigator 1 | Seqirus USA Inc | $3,268.53 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266191 |
| Principal investigator 1 | Seqirus USA Inc | $3,268.53 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266193 |
| Principal investigator 1 | Seqirus USA Inc | $3,268.53 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266195 |
| Principal investigator 1 | Seqirus USA Inc | $3,268.53 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266197 |
| Principal investigator 1 | Seqirus USA Inc | $3,268.53 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266199 |
| Principal investigator 1 | Seqirus USA Inc | $3,268.53 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266201 |
| Principal investigator 1 | Seqirus USA Inc | $3,268.53 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266203 |
| Principal investigator 1 | Seqirus USA Inc | $3,268.53 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266206 |
| Principal investigator 1 | Seqirus USA Inc | $3,268.53 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266209 |
| Principal investigator 1 | Seqirus USA Inc | $3,268.53 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266211 |
| Principal investigator 1 | Seqirus USA Inc | $3,268.53 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266213 |
| Principal investigator 1 | Seqirus USA Inc | $3,268.53 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266215 |
| Principal investigator 1 | Seqirus USA Inc | $3,268.53 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266217 |
| Principal investigator 1 | Seqirus USA Inc | $3,268.53 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266219 |
| Principal investigator 1 | Seqirus USA Inc | $3,268.53 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266221 |
| Principal investigator 1 | Seqirus USA Inc | $3,268.53 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266223 |
| Principal investigator 1 | Seqirus USA Inc | $3,268.53 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266225 |
| Principal investigator 1 | Seqirus USA Inc | $3,268.53 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266227 |
| Principal investigator 1 | Seqirus USA Inc | $3,268.53 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266231 |
| Principal investigator 1 | Seqirus USA Inc | $3,268.53 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266233 |
| Principal investigator 1 | Seqirus USA Inc | $3,268.53 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266235 |
| Principal investigator 1 | Seqirus USA Inc | $3,268.53 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266237 |
| Principal investigator 1 | Seqirus USA Inc | $3,268.53 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266239 |
| Principal investigator 1 | Seqirus USA Inc | $3,268.53 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266241 |
| Principal investigator 1 | Seqirus USA Inc | $3,268.53 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266243 |
| Principal investigator 1 | Seqirus USA Inc | $3,268.53 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266245 |
| Principal investigator 1 | Seqirus USA Inc | $3,268.53 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266247 |
| Principal investigator 1 | Seqirus USA Inc | $3,268.53 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266249 |
| Principal investigator 1 | Seqirus USA Inc | $3,268.53 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266251 |
| Principal investigator 1 | Seqirus USA Inc | $3,268.53 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266253 |
| Principal investigator 1 | Seqirus USA Inc | $3,268.53 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266255 |
| Principal investigator 1 | Seqirus USA Inc | $3,268.53 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266257 |
| Principal investigator 1 | Seqirus USA Inc | $3,268.53 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266259 |
| Principal investigator 1 | Seqirus USA Inc | $3,268.53 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266261 |
| Principal investigator 1 | Seqirus USA Inc | $793.50 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266263 |
| Principal investigator 1 | Seqirus USA Inc | $793.50 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266265 |
| Principal investigator 1 | Seqirus USA Inc | $385.02 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266275 |
| Principal investigator 1 | Seqirus USA Inc | $385.02 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266277 |
| Principal investigator 1 | Seqirus USA Inc | $385.02 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266279 |
| Principal investigator 1 | Seqirus USA Inc | $385.02 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266281 |
| Principal investigator 1 | Seqirus USA Inc | $385.02 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266283 |
| Principal investigator 1 | Seqirus USA Inc | $385.02 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266393 |
| Principal investigator 1 | Seqirus USA Inc | $793.50 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266395 |
| Principal investigator 1 | Seqirus USA Inc | $1,080.54 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266399 |
| Principal investigator 1 | Seqirus USA Inc | $1,207.50 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266401 |
| Principal investigator 1 | Seqirus USA Inc | $3,268.53 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266405 |
| Principal investigator 1 | Seqirus USA Inc | $1,207.50 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266415 |
| Principal investigator 1 | Seqirus USA Inc | $1,080.54 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266417 |
| Principal investigator 1 | Seqirus USA Inc | $1,080.54 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266419 |
| Principal investigator 1 | Seqirus USA Inc | $1,080.54 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266421 |
| Principal investigator 1 | Seqirus USA Inc | $1,080.54 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266423 |
| Principal investigator 1 | Seqirus USA Inc | $1,080.54 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266425 |
| Principal investigator 1 | Seqirus USA Inc | $1,080.54 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266427 |
| Principal investigator 1 | Seqirus USA Inc | $1,080.54 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266429 |
| Principal investigator 1 | Seqirus USA Inc | $1,080.54 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266431 |
| Principal investigator 1 | Seqirus USA Inc | $1,080.54 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266433 |
| Principal investigator 1 | Seqirus USA Inc | $1,080.54 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266435 |
| Principal investigator 1 | Seqirus USA Inc | $1,080.54 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266437 |
| Principal investigator 1 | Seqirus USA Inc | $1,080.54 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266439 |
| Principal investigator 1 | Seqirus USA Inc | $1,080.54 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266441 |
| Principal investigator 1 | Seqirus USA Inc | $1,080.54 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266443 |
| Principal investigator 1 | Seqirus USA Inc | $1,080.54 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266445 |
| Principal investigator 1 | Seqirus USA Inc | $1,080.54 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266447 |
| Principal investigator 1 | Seqirus USA Inc | $1,080.54 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266449 |
| Principal investigator 1 | Seqirus USA Inc | $1,080.54 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266451 |
| Principal investigator 1 | Seqirus USA Inc | $1,080.54 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266453 |
| Principal investigator 1 | Seqirus USA Inc | $3,268.53 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266455 |
| Principal investigator 1 | Seqirus USA Inc | $3,268.53 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266457 |
| Principal investigator 1 | Seqirus USA Inc | $3,268.53 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266459 |
| Principal investigator 1 | Seqirus USA Inc | $3,268.53 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266461 |
| Principal investigator 1 | Seqirus USA Inc | $3,268.53 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266463 |
| Principal investigator 1 | Seqirus USA Inc | $3,268.53 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266465 |
| Principal investigator 1 | Seqirus USA Inc | $3,268.53 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266467 |
| Principal investigator 1 | Seqirus USA Inc | $3,268.53 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266469 |
| Principal investigator 1 | Seqirus USA Inc | $3,268.53 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266471 |
| Principal investigator 1 | Seqirus USA Inc | $3,268.53 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266473 |
| Principal investigator 1 | Seqirus USA Inc | $3,268.53 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266475 |
| Principal investigator 1 | Seqirus USA Inc | $3,268.53 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266477 |
| Principal investigator 1 | Seqirus USA Inc | $3,268.53 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266479 |
| Principal investigator 1 | Seqirus USA Inc | $3,268.53 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266481 |
| Principal investigator 1 | Seqirus USA Inc | $3,268.53 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266483 |
| Principal investigator 1 | Seqirus USA Inc | $3,268.53 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266486 |
| Principal investigator 1 | Seqirus USA Inc | $3,268.53 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266489 |
| Principal investigator 1 | Seqirus USA Inc | $3,268.53 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266491 |
| Principal investigator 1 | Seqirus USA Inc | $3,268.53 | 12/19/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266493 |
| Principal investigator 1 | ModernaTX, Inc. | $1,800.00 | 12/17/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252996726 |
| Principal investigator 1 | ModernaTX, Inc. | $800.00 | 12/17/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252996728 |
| Principal investigator 1 | ModernaTX, Inc. | $600.00 | 12/17/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252996770 |
| Principal investigator 1 | ModernaTX, Inc. | $75.00 | 12/17/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252996800 |
| Principal investigator 1 | ModernaTX, Inc. | $2,000.00 | 12/17/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252996804 |
| Principal investigator 1 | ModernaTX, Inc. | $1,200.00 | 12/17/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252996853 |
| Principal investigator 1 | ModernaTX, Inc. | $1,657.50 | 12/15/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996861 |
| Principal investigator 1 | ModernaTX, Inc. | $244.00 | 12/15/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996887 |
| Principal investigator 1 | ModernaTX, Inc. | $24,252.75 | 12/05/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age | No dispute reported | 06/30/2026 | 1252968183 |
| Principal investigator 1 | ModernaTX, Inc. | $318.50 | 12/04/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996736 |
| Principal investigator 1 | ModernaTX, Inc. | $1,860.00 | 11/27/2025 | Non-covered Recipient Entity Benchmark Research | A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age | No dispute reported | 06/30/2026 | 1252968125 |
| Principal investigator 1 | ModernaTX, Inc. | $2,966.00 | 11/27/2025 | Non-covered Recipient Entity Benchmark Research | A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age | No dispute reported | 06/30/2026 | 1252968193 |
| Principal investigator 1 | ModernaTX, Inc. | $600.00 | 11/27/2025 | Non-covered Recipient Entity Benchmark Research | A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age | No dispute reported | 06/30/2026 | 1252968213 |
| Principal investigator 1 | ModernaTX, Inc. | $2,000.00 | 11/27/2025 | Non-covered Recipient Entity Benchmark Research | A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age | No dispute reported | 06/30/2026 | 1252968215 |
| Principal investigator 1 | ModernaTX, Inc. | $4,284.00 | 11/27/2025 | Non-covered Recipient Entity Benchmark Research | A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age | No dispute reported | 06/30/2026 | 1252968217 |
| Principal investigator 1 | ModernaTX, Inc. | $1,800.00 | 11/27/2025 | Non-covered Recipient Entity Benchmark Research | A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age | No dispute reported | 06/30/2026 | 1252968219 |
| Principal investigator 1 | ModernaTX, Inc. | $10,600.00 | 11/27/2025 | Non-covered Recipient Entity Benchmark Research | A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age | No dispute reported | 06/30/2026 | 1252968223 |
| Principal investigator 1 | ModernaTX, Inc. | $50,933.28 | 11/27/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996810 |
| Principal investigator 1 | ModernaTX, Inc. | $671.84 | 11/27/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996814 |
| Principal investigator 1 | ModernaTX, Inc. | $7,349.76 | 11/27/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996825 |
| Principal investigator 1 | ModernaTX, Inc. | $136.60 | 11/26/2025 | Non-covered Recipient Entity Benchmark Research | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996822 |
| Principal investigator 1 | PFIZER INC. | $9,660.00 | 11/26/2025 | Non-covered Recipient Entity Qcare Site Services Inc | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228712840 |
| Principal investigator 1 | ModernaTX, Inc. | $250.00 | 11/14/2025 | Non-covered Recipient Entity LSB RESEARCH GROUP LLC | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252968107 |
| Principal investigator 1 | ModernaTX, Inc. | $4,490.10 | 11/14/2025 | Non-covered Recipient Entity QCARE SITE SERVICES | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1252968199 |
| Principal investigator 1 | PFIZER INC. | $1,277.78 | 10/31/2025 | Non-covered Recipient Entity Qcare Site Services Inc | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228824286 |
| Principal investigator 1 | Seqirus USA Inc | $3,846.60 | 10/31/2025 | Non-covered Recipient Entity Avacare Clinical Research Network | A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age | No dispute reported | 06/30/2026 | 1250809500 |
| Principal investigator 1 | Seqirus USA Inc | $1,057.05 | 10/31/2025 | Non-covered Recipient Entity Avacare Clinical Research Network | A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age | No dispute reported | 06/30/2026 | 1250809504 |
| Principal investigator 1 | ModernaTX, Inc. | $78.00 | 10/29/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996752 |
| Principal investigator 1 | ModernaTX, Inc. | $199.56 | 10/29/2025 | Non-covered Recipient Entity BENCHMARK RESEARCH | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996774 |
| Principal investigator 1 | ModernaTX, Inc. | $6,100.00 | 10/29/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996843 |
| Principal investigator 1 | ModernaTX, Inc. | $5,038.80 | 10/27/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996742 |
| Principal investigator 1 | ModernaTX, Inc. | $7,158.36 | 10/27/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996758 |
| Principal investigator 1 | ModernaTX, Inc. | $811.40 | 10/27/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996764 |
| Principal investigator 1 | PFIZER INC. | $388.00 | 10/25/2025 | Non-covered Recipient Entity Qcare Site Services Inc | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228824771 |
| Principal investigator 1 | PFIZER INC. | $1,500.00 | 10/25/2025 | Non-covered Recipient Entity LSB Research Group LLC dba Benchmark Research | A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228824833 |
| Principal investigator 1 | ModernaTX, Inc. | $2,250.00 | 10/22/2025 | Non-covered Recipient Entity LSB RESEARCH GROUP LLC | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252968147 |
| Principal investigator 1 | Seqirus USA Inc | $2,000.00 | 10/17/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266403 |
| Principal investigator 1 | Seqirus USA Inc | $3,500.00 | 10/17/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266407 |
| Principal investigator 1 | Seqirus USA Inc | $15,000.00 | 10/17/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266409 |
| Principal investigator 1 | ModernaTX, Inc. | $2,400.00 | 10/10/2025 | Non-covered Recipient Entity QCARE SITE SERVICES | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1252968127 |
| Principal investigator 1 | ModernaTX, Inc. | $1,050.00 | 10/10/2025 | Non-covered Recipient Entity QCARE SITE SERVICES | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1252968129 |
| Principal investigator 1 | ModernaTX, Inc. | $700.00 | 10/10/2025 | Non-covered Recipient Entity QCARE SITE SERVICES | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1252968197 |
| Principal investigator 1 | ModernaTX, Inc. | $78.00 | 10/09/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996780 |
| Principal investigator 1 | ModernaTX, Inc. | $1,060.80 | 10/09/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996792 |
| Principal investigator 1 | ModernaTX, Inc. | $1,622.40 | 10/09/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996859 |
| Principal investigator 1 | ModernaTX, Inc. | $1,952.00 | 10/09/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996883 |
| Principal investigator 1 | PFIZER INC. | $21,272.65 | 10/08/2025 | Non-covered Recipient Entity Qcare Site Services Inc | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228824778 |
| Principal investigator 1 | ModernaTX, Inc. | $6,382.48 | 09/29/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996831 |
| Principal investigator 1 | ModernaTX, Inc. | $6,737.28 | 09/29/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996841 |
| Principal investigator 1 | PFIZER INC. | $3,000.00 | 09/24/2025 | Non-covered Recipient Entity LSB Research Group LLC dba Benchmark Research | A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228837332 |
| Principal investigator 1 | ModernaTX, Inc. | $318.50 | 09/22/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996827 |
| Principal investigator 1 | Seqirus USA Inc | $110.98 | 09/18/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266389 |
| Principal investigator 1 | Seqirus USA Inc | $111.30 | 09/18/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266391 |
| Principal investigator 1 | Seqirus USA Inc | $946.80 | 09/18/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185266397 |
| Principal investigator 1 | ModernaTX, Inc. | $400.00 | 09/17/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age | No dispute reported | 06/30/2026 | 1252968151 |
| Principal investigator 1 | ModernaTX, Inc. | $700.00 | 09/17/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age | No dispute reported | 06/30/2026 | 1252968153 |
| Principal investigator 1 | ModernaTX, Inc. | $900.00 | 09/17/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age | No dispute reported | 06/30/2026 | 1252968187 |
| Principal investigator 1 | ModernaTX, Inc. | $1,892.70 | 09/12/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1252968131 |
| Principal investigator 1 | ModernaTX, Inc. | $11,300.00 | 09/11/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252996724 |
| Principal investigator 1 | ModernaTX, Inc. | $2,250.00 | 09/11/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252996730 |
| Principal investigator 1 | ModernaTX, Inc. | $8,400.00 | 09/11/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252996732 |
| Principal investigator 1 | ModernaTX, Inc. | $3,000.00 | 09/11/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252996802 |
| Principal investigator 1 | ModernaTX, Inc. | $1,050.00 | 09/11/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252996849 |
| Principal investigator 1 | ModernaTX, Inc. | $2,775.00 | 09/11/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252996851 |
| Principal investigator 1 | ModernaTX, Inc. | $20,668.50 | 09/10/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age | No dispute reported | 06/30/2026 | 1252968115 |
| Principal investigator 1 | ModernaTX, Inc. | $2,500.00 | 09/10/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age | No dispute reported | 06/30/2026 | 1252968117 |
| Principal investigator 1 | ModernaTX, Inc. | $742.50 | 09/10/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age | No dispute reported | 06/30/2026 | 1252968149 |
| Principal investigator 1 | Seqirus USA Inc | $420.00 | 09/10/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185266353 |
| Principal investigator 1 | Seqirus USA Inc | $24.00 | 09/10/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185266355 |
| Principal investigator 1 | Seqirus USA Inc | $164.28 | 09/10/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185266357 |
| Principal investigator 1 | ModernaTX, Inc. | $318.50 | 09/03/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996766 |
| Principal investigator 1 | ModernaTX, Inc. | $18,475.60 | 08/28/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996762 |
| Principal investigator 1 | ModernaTX, Inc. | $7,866.54 | 08/28/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996879 |
| Principal investigator 1 | ModernaTX, Inc. | $4,456.88 | 08/28/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996891 |
| Principal investigator 1 | ModernaTX, Inc. | $418.66 | 08/28/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253002485 |
| Principal investigator 1 | ModernaTX, Inc. | $138.32 | 08/28/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011232 |
| Principal investigator 1 | ModernaTX, Inc. | $3,888.40 | 08/20/2025 | Non-covered Recipient Entity LSB RESEARCH GROUP LLC | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252968203 |
| Principal investigator 1 | ModernaTX, Inc. | $4,860.50 | 08/01/2025 | Non-covered Recipient Entity LSB RESEARCH GROUP LLC | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252968181 |
| Principal investigator 1 | ModernaTX, Inc. | $76,950.00 | 08/01/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age | No dispute reported | 06/30/2026 | 1252968185 |
| Principal investigator 1 | ModernaTX, Inc. | $1,837.44 | 07/28/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996744 |
| Principal investigator 1 | ModernaTX, Inc. | $7,799.54 | 07/28/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996778 |
| Principal investigator 1 | ModernaTX, Inc. | $9,652.50 | 07/23/2025 | Non-covered Recipient Entity QCARE SITE SERVICES | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1252968135 |
| Principal investigator 1 | ModernaTX, Inc. | $5,031.45 | 07/23/2025 | Non-covered Recipient Entity QCARE SITE SERVICES | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1252968171 |
| Principal investigator 1 | Seqirus USA Inc | $900.00 | 07/18/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185266369 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $8,900.00 | 07/16/2025 | Non-covered Recipient Entity BENCHMARK RESEARCH | a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older | No dispute reported | 06/30/2026 | 1185546143 |
| Principal investigator 1 | Seqirus USA Inc | $172.00 | 07/14/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185266361 |
| Principal investigator 1 | Seqirus USA Inc | $1,200.00 | 07/14/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185266363 |
| Principal investigator 1 | Seqirus USA Inc | $8,500.00 | 07/14/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185266365 |
| Principal investigator 1 | Seqirus USA Inc | $1,500.00 | 07/14/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185266367 |
| Principal investigator 1 | Seqirus USA Inc | $1,500.00 | 07/14/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185266377 |
| Principal investigator 1 | PFIZER INC. | $3,712.00 | 07/11/2025 | Non-covered Recipient Entity Qcare Site Services Inc | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228846932 |
| Principal investigator 1 | PFIZER INC. | $184.65 | 07/07/2025 | Non-covered Recipient Entity Benchmark Research | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228712842 |
| Principal investigator 1 | PFIZER INC. | $216.45 | 07/07/2025 | Non-covered Recipient Entity Benchmark Research | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228712844 |
| Principal investigator 1 | ModernaTX, Inc. | $114.75 | 07/02/2025 | Non-covered Recipient Entity LSB RESEARCH GROUP LLC | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252968105 |
| Principal investigator 1 | ModernaTX, Inc. | $4,374.45 | 07/02/2025 | Non-covered Recipient Entity LSB RESEARCH GROUP LLC | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252968201 |
| Principal investigator 1 | Seqirus USA Inc | $2,350.00 | 07/02/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185266345 |
| Principal investigator 1 | Seqirus USA Inc | $1,500.00 | 07/02/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185266347 |
| Principal investigator 1 | Seqirus USA Inc | $1,200.00 | 07/02/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185266349 |
| Principal investigator 1 | Seqirus USA Inc | $1,800.00 | 07/02/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185266351 |
| Principal investigator 1 | PFIZER INC. | $4,300.00 | 07/01/2025 | Non-covered Recipient Entity Qcare Site Services Inc dba Avacare | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228846939 |
| Principal investigator 1 | ModernaTX, Inc. | $5,742.00 | 06/27/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996829 |
| Principal investigator 1 | ModernaTX, Inc. | $2,687.36 | 06/27/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996877 |
| Principal investigator 1 | ModernaTX, Inc. | $7,799.54 | 06/27/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996881 |
| Principal investigator 1 | ModernaTX, Inc. | $2,450.25 | 06/25/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1252968133 |
| Principal investigator 1 | ModernaTX, Inc. | $900.00 | 06/25/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1252968137 |
| Principal investigator 1 | ModernaTX, Inc. | $364.50 | 06/25/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1252968161 |
| Principal investigator 1 | ModernaTX, Inc. | $121.50 | 06/25/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1252968163 |
| Principal investigator 1 | ModernaTX, Inc. | $1,200.00 | 06/25/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1252968165 |
| Principal investigator 1 | ModernaTX, Inc. | $22,889.25 | 06/18/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1252968169 |
| Principal investigator 1 | ModernaTX, Inc. | $2,434.20 | 06/18/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996738 |
| Principal investigator 1 | ModernaTX, Inc. | $5,374.72 | 06/18/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996790 |
| Principal investigator 1 | ModernaTX, Inc. | $6,469.32 | 06/18/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996796 |
| Principal investigator 1 | ModernaTX, Inc. | $25,627.06 | 06/18/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996816 |
| Principal investigator 1 | ModernaTX, Inc. | $2,093.30 | 06/18/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253002483 |
| Principal investigator 1 | ModernaTX, Inc. | $528.00 | 06/04/2025 | Non-covered Recipient Entity BENCHMARK RESEARCH | A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age | No dispute reported | 06/30/2026 | 1252968211 |
| Principal investigator 1 | ModernaTX, Inc. | $245.00 | 06/04/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011222 |
| Principal investigator 1 | ModernaTX, Inc. | $23,962.50 | 05/28/2025 | Non-covered Recipient Entity BENCHMARK RESEARCH | A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age | No dispute reported | 06/30/2026 | 1252968121 |
| Principal investigator 1 | ModernaTX, Inc. | $6,521.85 | 05/28/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1252968167 |
| Principal investigator 1 | ModernaTX, Inc. | $57,939.44 | 05/28/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996734 |
| Principal investigator 1 | ModernaTX, Inc. | $13,772.72 | 05/28/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996748 |
| Principal investigator 1 | ModernaTX, Inc. | $7,215.78 | 05/28/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996871 |
| Principal investigator 1 | ModernaTX, Inc. | $55,681.78 | 05/28/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011214 |
| Principal investigator 1 | ModernaTX, Inc. | $1,420.25 | 05/28/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011228 |
| Principal investigator 1 | ModernaTX, Inc. | $11,520.08 | 05/28/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011236 |
| Principal investigator 1 | ModernaTX, Inc. | $83,868.75 | 05/22/2025 | Non-covered Recipient Entity BENCHMARK RESEARCH | A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age | No dispute reported | 06/30/2026 | 1252968221 |
| Principal investigator 1 | ModernaTX, Inc. | $486.05 | 05/21/2025 | Non-covered Recipient Entity LSB RESEARCH GROUP LLC | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252968109 |
| Principal investigator 1 | ModernaTX, Inc. | $39.00 | 05/15/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996835 |
| Principal investigator 1 | ModernaTX, Inc. | $2,121.60 | 05/15/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996837 |
| Principal investigator 1 | ModernaTX, Inc. | $70,842.60 | 05/14/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age | No dispute reported | 06/30/2026 | 1252968113 |
| Principal investigator 1 | ModernaTX, Inc. | $1,500.00 | 05/14/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996865 |
| Principal investigator 1 | ModernaTX, Inc. | $22,634.10 | 05/07/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1252968195 |
| Principal investigator 1 | PFIZER INC. | $898.43 | 05/07/2025 | Non-covered Recipient Entity Qcare Site Services Inc | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228857518 |
| Principal investigator 1 | ModernaTX, Inc. | $33,256.08 | 04/28/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996812 |
| Principal investigator 1 | ModernaTX, Inc. | $6,679.86 | 04/28/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996847 |
| Principal investigator 1 | ModernaTX, Inc. | $1,622.80 | 04/28/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996873 |
| Principal investigator 1 | ModernaTX, Inc. | $19,258.36 | 04/28/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253002489 |
| Principal investigator 1 | ModernaTX, Inc. | $19,028.88 | 04/28/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011224 |
| Principal investigator 1 | ModernaTX, Inc. | $12,782.25 | 04/28/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011226 |
| Principal investigator 1 | ModernaTX, Inc. | $3,773.40 | 04/23/2025 | Non-covered Recipient Entity LSB RESEARCH GROUP LLC | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252968143 |
| Principal investigator 1 | Seqirus USA Inc | $638.00 | 04/09/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185266295 |
| Principal investigator 1 | Seqirus USA Inc | $638.00 | 04/09/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185266297 |
| Principal investigator 1 | Seqirus USA Inc | $638.00 | 04/09/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185266299 |
| Principal investigator 1 | Seqirus USA Inc | $638.00 | 04/09/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185266301 |
| Principal investigator 1 | Seqirus USA Inc | $638.00 | 04/09/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185266303 |
| Principal investigator 1 | Seqirus USA Inc | $638.00 | 04/09/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185266305 |
| Principal investigator 1 | Seqirus USA Inc | $1,291.00 | 04/09/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185266307 |
| Principal investigator 1 | Seqirus USA Inc | $638.00 | 04/09/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185266309 |
| Principal investigator 1 | Seqirus USA Inc | $638.00 | 04/09/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185266311 |
| Principal investigator 1 | Seqirus USA Inc | $638.00 | 04/09/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185266313 |
| Principal investigator 1 | Seqirus USA Inc | $638.00 | 04/09/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185266315 |
| Principal investigator 1 | Seqirus USA Inc | $638.00 | 04/09/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185266317 |
| Principal investigator 1 | Seqirus USA Inc | $638.00 | 04/09/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185266319 |
| Principal investigator 1 | Seqirus USA Inc | $638.00 | 04/09/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185266321 |
| Principal investigator 1 | Seqirus USA Inc | $638.00 | 04/09/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185266323 |
| Principal investigator 1 | Seqirus USA Inc | $1,291.00 | 04/09/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185266325 |
| Principal investigator 1 | Seqirus USA Inc | $638.00 | 04/09/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185266327 |
| Principal investigator 1 | Seqirus USA Inc | $638.00 | 04/09/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185266329 |
| Principal investigator 1 | Seqirus USA Inc | $638.00 | 04/09/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185266331 |
| Principal investigator 1 | Seqirus USA Inc | $638.00 | 04/09/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185266333 |
| Principal investigator 1 | Seqirus USA Inc | $638.00 | 04/09/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185266335 |
| Principal investigator 1 | Seqirus USA Inc | $638.00 | 04/09/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185266337 |
| Principal investigator 1 | Seqirus USA Inc | $1,291.00 | 04/09/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185266555 |
| Principal investigator 1 | Seqirus USA Inc | $638.00 | 04/09/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185266557 |
| Principal investigator 1 | Seqirus USA Inc | $638.00 | 04/09/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185266559 |
| Principal investigator 1 | Seqirus USA Inc | $1,291.00 | 04/09/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185266561 |
| Principal investigator 1 | Seqirus USA Inc | $638.00 | 04/09/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185266563 |
| Principal investigator 1 | Seqirus USA Inc | $638.00 | 04/09/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185266565 |
| Principal investigator 1 | Seqirus USA Inc | $638.00 | 04/09/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185266567 |
| Principal investigator 1 | Seqirus USA Inc | $638.00 | 04/09/2025 | Non-covered Recipient Entity Qcare Site Services Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185266569 |
| Principal investigator 1 | ModernaTX, Inc. | $156.00 | 04/01/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996784 |
| Principal investigator 1 | ModernaTX, Inc. | $12,870.00 | 04/01/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253002487 |
| Principal investigator 1 | ModernaTX, Inc. | $182.00 | 04/01/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011216 |
| Principal investigator 1 | ModernaTX, Inc. | $1,170.00 | 03/28/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011218 |
| Principal investigator 1 | ModernaTX, Inc. | $9,585.00 | 03/24/2025 | Non-covered Recipient Entity BENCHMARK RESEARCH | A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age | No dispute reported | 06/30/2026 | 1252968123 |
| Principal investigator 1 | ModernaTX, Inc. | $3,245.60 | 03/24/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996746 |
| Principal investigator 1 | ModernaTX, Inc. | $6,105.66 | 03/24/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996754 |
| Principal investigator 1 | ModernaTX, Inc. | $9,903.42 | 03/24/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996845 |
| Principal investigator 1 | ModernaTX, Inc. | $30,568.72 | 03/24/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996863 |
| Principal investigator 1 | ModernaTX, Inc. | $2,511.96 | 03/24/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253002497 |
| Principal investigator 1 | ModernaTX, Inc. | $17,210.96 | 03/24/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011208 |
| Principal investigator 1 | ModernaTX, Inc. | $11,362.00 | 03/24/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011210 |
| Principal investigator 1 | PFIZER INC. | $4,002.04 | 03/22/2025 | Non-covered Recipient Entity LSB Research Group LLC dba Benchmark Research | A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228862098 |
| Principal investigator 1 | PFIZER INC. | $2,228.16 | 03/22/2025 | Non-covered Recipient Entity Qcare Site Services Inc dba Avacare | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228862799 |
| Principal investigator 1 | ModernaTX, Inc. | $675.00 | 03/19/2025 | Non-covered Recipient Entity LSB RESEARCH GROUP LLC | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252968141 |
| Principal investigator 1 | ModernaTX, Inc. | $2,430.25 | 03/19/2025 | Non-covered Recipient Entity LSB RESEARCH GROUP LLC | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252968179 |
| Principal investigator 1 | PFIZER INC. | $898.43 | 03/12/2025 | Non-covered Recipient Entity Qcare Site Services Inc | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228862992 |
| Principal investigator 1 | PFIZER INC. | $4,492.15 | 03/05/2025 | Non-covered Recipient Entity Qcare Site Services Inc | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228863002 |
| Principal investigator 1 | ModernaTX, Inc. | $3,981.12 | 02/27/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996760 |
| Principal investigator 1 | ModernaTX, Inc. | $3,151.72 | 02/27/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996794 |
| Principal investigator 1 | ModernaTX, Inc. | $9,876.42 | 02/27/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996820 |
| Principal investigator 1 | ModernaTX, Inc. | $7,751.70 | 02/27/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996833 |
| Principal investigator 1 | ModernaTX, Inc. | $27,881.36 | 02/27/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996839 |
| Principal investigator 1 | ModernaTX, Inc. | $16,505.70 | 02/27/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996855 |
| Principal investigator 1 | ModernaTX, Inc. | $33,285.20 | 02/27/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996869 |
| Principal investigator 1 | ModernaTX, Inc. | $811.40 | 02/27/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996875 |
| Principal investigator 1 | ModernaTX, Inc. | $8,032.48 | 02/27/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253002491 |
| Principal investigator 1 | ModernaTX, Inc. | $9,941.75 | 02/27/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011206 |
| Principal investigator 1 | ModernaTX, Inc. | $516.24 | 02/27/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011212 |
| Principal investigator 1 | ModernaTX, Inc. | $44,796.62 | 02/27/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011220 |
| Principal investigator 1 | ModernaTX, Inc. | $33,018.96 | 02/27/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011230 |
| Principal investigator 1 | ModernaTX, Inc. | $600.00 | 02/26/2025 | Non-covered Recipient Entity LSB RESEARCH GROUP LLC | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252968139 |
| Principal investigator 1 | ModernaTX, Inc. | $2,605.50 | 02/26/2025 | Non-covered Recipient Entity LSB RESEARCH GROUP LLC | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252968175 |
| Principal investigator 1 | ModernaTX, Inc. | $229.50 | 02/26/2025 | Non-covered Recipient Entity LSB RESEARCH GROUP LLC | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252968177 |
| Principal investigator 1 | PFIZER INC. | $1,796.86 | 02/26/2025 | Non-covered Recipient Entity Qcare Site Services Inc | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228838034 |
| Principal investigator 1 | PFIZER INC. | $8,004.08 | 02/22/2025 | Non-covered Recipient Entity LSB Research Group LLC dba Benchmark Research | A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228837338 |
| Principal investigator 1 | ModernaTX, Inc. | $7,316.80 | 02/21/2025 | Non-covered Recipient Entity LSB RESEARCH GROUP LLC | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252968145 |
| Principal investigator 1 | ModernaTX, Inc. | $1,060.80 | 02/19/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996776 |
| Principal investigator 1 | ModernaTX, Inc. | $7,300.00 | 02/14/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996740 |
| Principal investigator 1 | ModernaTX, Inc. | $1,500.00 | 02/14/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996750 |
| Principal investigator 1 | ModernaTX, Inc. | $1,723.80 | 02/14/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996782 |
| Principal investigator 1 | ModernaTX, Inc. | $1,100.00 | 02/14/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996867 |
| Principal investigator 1 | ModernaTX, Inc. | $455.00 | 02/14/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996885 |
| Principal investigator 1 | ModernaTX, Inc. | $2,000.00 | 02/14/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996889 |
| Principal investigator 1 | PFIZER INC. | $1,143.44 | 02/05/2025 | Non-covered Recipient Entity LSB Research Group LLC dba Benchmark Research | A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228837346 |
| Principal investigator 1 | PFIZER INC. | $5,717.20 | 01/30/2025 | Non-covered Recipient Entity LSB Research Group LLC dba Benchmark Research | A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228862583 |
| Principal investigator 1 | ModernaTX, Inc. | $5,545.10 | 01/29/2025 | Non-covered Recipient Entity LSB RESEARCH GROUP LLC | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252968173 |
| Principal investigator 1 | ModernaTX, Inc. | $125.00 | 01/29/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252996772 |
| Principal investigator 1 | ModernaTX, Inc. | $29,840.40 | 01/29/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252996798 |
| Principal investigator 1 | ModernaTX, Inc. | $3,655.74 | 01/27/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996756 |
| Principal investigator 1 | ModernaTX, Inc. | $267.96 | 01/27/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996768 |
| Principal investigator 1 | ModernaTX, Inc. | $22,062.04 | 01/27/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996786 |
| Principal investigator 1 | ModernaTX, Inc. | $15,452.32 | 01/27/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996788 |
| Principal investigator 1 | ModernaTX, Inc. | $811.40 | 01/27/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996806 |
| Principal investigator 1 | ModernaTX, Inc. | $15,405.32 | 01/27/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996857 |
| Principal investigator 1 | ModernaTX, Inc. | $23,020.40 | 01/27/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253002493 |
| Principal investigator 1 | ModernaTX, Inc. | $82,332.92 | 01/27/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253002495 |
| Principal investigator 1 | ModernaTX, Inc. | $6,698.56 | 01/27/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253002499 |
| Principal investigator 1 | ModernaTX, Inc. | $29,112.60 | 01/27/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011234 |
| Principal investigator 1 | PFIZER INC. | $317.40 | 01/25/2025 | Non-covered Recipient Entity Qcare Site Services Inc dba Avacare | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228863621 |
| Principal investigator 1 | ModernaTX, Inc. | $90.00 | 01/24/2025 | Non-covered Recipient Entity LSB RESEARCH GROUP LLC | A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas | No dispute reported | 06/30/2026 | 1252968119 |
| Principal investigator 1 | ModernaTX, Inc. | $6,307.00 | 01/24/2025 | Non-covered Recipient Entity LSB RESEARCH GROUP LLC | A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas | No dispute reported | 06/30/2026 | 1252968155 |
| Principal investigator 1 | ModernaTX, Inc. | $2,250.00 | 01/24/2025 | Non-covered Recipient Entity LSB RESEARCH GROUP LLC | A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas | No dispute reported | 06/30/2026 | 1252968157 |
| Principal investigator 1 | ModernaTX, Inc. | $170.00 | 01/24/2025 | Non-covered Recipient Entity LSB RESEARCH GROUP LLC | A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas | No dispute reported | 06/30/2026 | 1252968159 |
| Principal investigator 1 | ModernaTX, Inc. | $3,968.00 | 01/24/2025 | Non-covered Recipient Entity LSB RESEARCH GROUP LLC | A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas | No dispute reported | 06/30/2026 | 1252968189 |
| Principal investigator 1 | ModernaTX, Inc. | $114.00 | 01/24/2025 | Non-covered Recipient Entity LSB RESEARCH GROUP LLC | A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas | No dispute reported | 06/30/2026 | 1252968191 |
| Principal investigator 1 | ModernaTX, Inc. | $8,625.00 | 01/24/2025 | Non-covered Recipient Entity LSB RESEARCH GROUP LLC | A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas | No dispute reported | 06/30/2026 | 1252968205 |
| Principal investigator 1 | ModernaTX, Inc. | $625.00 | 01/24/2025 | Non-covered Recipient Entity LSB RESEARCH GROUP LLC | A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas | No dispute reported | 06/30/2026 | 1252968207 |
| Principal investigator 1 | ModernaTX, Inc. | $110.00 | 01/24/2025 | Non-covered Recipient Entity LSB RESEARCH GROUP LLC | A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas | No dispute reported | 06/30/2026 | 1252968209 |
| Principal investigator 1 | ModernaTX, Inc. | $199.56 | 01/13/2025 | Non-covered Recipient Entity BENCHMARK RESEARCH | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252996818 |
| Principal investigator 1 | ModernaTX, Inc. | $5,487.60 | 01/03/2025 | Non-covered Recipient Entity LSB RESEARCH GROUP LLC | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252968111 |